MedPath

BAYER AG

BAYER AG logo
🇩🇪Germany
Ownership
Public
Established
1863-08-01
Employees
99.7K
Market Cap
$30.1B
Website
http://www.bayer.com
Clinical Trials
Related News

Efficacy and Safety of CIPRO XR Versus CIPRO IR in Patients With Complicated Urinary Tract Infections

Phase 3
Completed
Conditions
Urinary Tract Infection
Interventions
Drug: Cipro IR (Ciprofloxacin, BAYQ3939)
Drug: Cipro XR (Ciprofloxacin, BAYQ3939)
First Posted Date
2008-04-28
Last Posted Date
2009-06-30
Lead Sponsor
Bayer
Target Recruit Count
212
Registration Number
NCT00668122

Evaluating the Efficacy of Vardenafil in Subjects With Erectile Dysfunction (ED) Administered 12, 18 or 24 Hours Prior to Intercourse

Phase 4
Completed
Conditions
Erectile Dysfunction
Interventions
Drug: Levitra (Vardenafil, BAY38-9456)
Drug: Placebo
First Posted Date
2008-04-28
Last Posted Date
2009-06-30
Lead Sponsor
Bayer
Target Recruit Count
264
Registration Number
NCT00667979

Assess Efficacy of Vardenafil 10mg in Erectile Dysfunction Within Intake of 6 Hours

Phase 3
Completed
Conditions
Erectile Dysfunction
Interventions
Drug: Levitra (Vardenafil, BAY38-9456)
First Posted Date
2008-04-28
Last Posted Date
2014-12-23
Lead Sponsor
Bayer
Target Recruit Count
887
Registration Number
NCT00668018

Effect of Aprotinin on Transfusion Requirements and Blood Loss in Patients Undergoing Elective Primary Total Hip Replacement

Phase 3
Completed
Conditions
Blood Loss, Surgical
Interventions
Drug: Trasylol (Aprotinin, BAYA0128)
Drug: Placebo
First Posted Date
2008-04-28
Last Posted Date
2014-12-30
Lead Sponsor
Bayer
Target Recruit Count
359
Registration Number
NCT00668031

Assessment of Efficacy of Vardenafil in Subjects With Erectile Dysfunction and Diabetes, Hypertension or Hyperlipidemia

Phase 3
Completed
Conditions
Erectile Dysfunction
Interventions
Drug: Levitra (Vardenafil, BAY38-9456)
Drug: Tadalafil
First Posted Date
2008-04-28
Last Posted Date
2014-12-23
Lead Sponsor
Bayer
Target Recruit Count
614
Registration Number
NCT00668109

Evaluating the Efficacy and Safety of Vardenafil in Subjects With Erectile Dysfunction and Hypertension

Phase 3
Completed
Conditions
Erectile Dysfunction
Interventions
Drug: Placebo
Drug: Levitra (Vardenafil, BAY38-9456)
First Posted Date
2008-04-28
Last Posted Date
2014-12-16
Lead Sponsor
Bayer
Target Recruit Count
388
Registration Number
NCT00668005

Ciprofloxacin on Burned Patients

Phase 3
Completed
Conditions
Burns
Bacterial Infections
Interventions
Drug: Ciprofloxacin (BAYO9867)
First Posted Date
2008-04-28
Last Posted Date
2009-10-27
Lead Sponsor
Bayer
Target Recruit Count
18
Registration Number
NCT00668044

PK in Pts With HRPC & Skeletal Metastes

Phase 1
Completed
Conditions
Prostatic Neoplasms
Interventions
Drug: Radium-223 chloride (Xofigo®, BAY88-8223) injection
First Posted Date
2008-04-28
Last Posted Date
2015-12-14
Lead Sponsor
Bayer
Target Recruit Count
6
Registration Number
NCT00667537

Assess Efficacy in Subjects With Traumatic Spinal Cord Injury

Phase 4
Completed
Conditions
Spinal Cord Injury
Erectile Dysfunction
Interventions
Drug: Vardenafil (Levitra, BAY 38-9456), 10 mg
Drug: Placebo
Drug: Vardenafil (Levitra, BAY 38-9456), 20 mg
First Posted Date
2008-04-28
Last Posted Date
2015-05-06
Lead Sponsor
Bayer
Target Recruit Count
45
Registration Number
NCT00667966

BAY38-9456 (Vardenafil HCL Tablet) in ED Treatment for China Registration.

Phase 3
Completed
Conditions
Erectile Dysfunction
Interventions
Drug: Levitra (Vardenafil, BAY38-9456)
Drug: Placebo
First Posted Date
2008-04-28
Last Posted Date
2015-03-06
Lead Sponsor
Bayer
Target Recruit Count
624
Registration Number
NCT00668057
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy